Hyperuricemia as an independent risk factor for major cardiovascular events
Authors:
- Federica MarcheseFMFederica Marchese
- Rocco CapuanoRCRocco Capuano
- Sergio TorreSTSergio Torre
- Anna G. IannoneAIAnna G. Iannone
- Eduardo CapuanoECEduardo Capuano
- Norman LamaidaNLNorman Lamaida
- Matteo SondereggerMSMatteo Sonderegger
- Ernesto CapuanoECErnesto Capuano
- 1 March 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Medicine
- Vol. 18 (3) , 159-164
Abstract
To date, whether hyperuricemia may represent a marker or an independent risk factor for cardiovascular disease remains unclear. This study aimed at assessing the role of hyperuricemia in the onset of major cardiovascular events (MACE). Baseline clinical data were collected through a 1998/1999 longitudinal survey as part of the larger Valle dell’Irno Prevenzione Project. Ten years later, MACE incidence was evaluated. A total of 1175 patients (50% men, aged 25–74 years) completed the study. At least one MACE was reported by 135 patients, whose mean uric acid values were significantly higher compared with patients without events (6.0 ± 4.8 and 4.6 ± 4.0 mg/dl, respectively; P < 0.01). Patients with uric acid values of at least 6 mg/dl (prevalence of 14.6%) had significantly lower levels of high-density lipoprotein cholesterol and increased values of BMI, blood pressure (BP), cholesterol, triglycerides, white blood cells, complement component 3 (C3) and creatinine. After subgrouping patients in tertiles and considering the first one as reference [odds ratio (OR): 1], the OR (95% confidence interval) was 1.44 (0.7–2.9) in the second and 2.2 (1.3–3.5) in the third tertile, respectively. Confounder-adjusted stepwise linear regression revealed uric acid, age, creatinine, glucose and systolic BP as independent predictors of MACE. Diastolic BP and creatinine were independently correlated with uric acid in the entire population, diastolic BP only in men and BMI, creatinine, age and C3 in women. Hyperuricemia was shown to be a strong independent risk factor for MACE and should be included in cardiovascular prevention strategies. Whether hypouricemic drugs can decrease cardiovascular disease risk warrants further studies.Keywords
This publication has 51 references indexed in Scilit:
- Hyperuricemia as an Independent Predictor of Vascular Complications and Mortality in Type 2 Diabetes Patients: A Meta-AnalysisPLOS ONE, 2013
- The Age-Specific Quantitative Effects of Metabolic Risk Factors on Cardiovascular Diseases and Diabetes: A Pooled AnalysisPLOS ONE, 2013
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)European Heart Journal, 2012
- Allopurinol Use Yields Potentially Beneficial Effects on Inflammatory Indices in Those With Recent Ischemic StrokeStroke, 2008
- Uric Acid and Cardiovascular RiskNew England Journal of Medicine, 2008
- Association Between Serum Uric Acid and Perioperative and Late Cardiovascular Outcome in Patients With Suspected or Definite Coronary Artery Disease Undergoing Elective Vascular SurgeryThe American Journal of Cardiology, 2008
- Menopause, postmenopausal hormone use and serum uric acid levels in US women – The Third National Health and Nutrition Examination SurveyArthritis Research & Therapy, 2008
- The paradoxical relationship between serum uric acid and cardiovascular diseaseClinica Chimica Acta, 2008
- Febuxostat Compared with Allopurinol in Patients with Hyperuricemia and GoutNew England Journal of Medicine, 2005
- Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular riskThe American Journal of Cardiology, 2004